The DOI matches its Crossref record.
Role of Multidrug Resistance 3 Deficiency in Pediatric and Adult Liver Disease: One Gene for Three Diseases
Abstract
Class III multidrug resistance P-glycoproteins, mdr2 in mice and MDR3 in humans, are canalicular phospholipid translocators involved in biliary phospholipid (phosphatidylcholine) excretion. The role of an MDR3 gene defect in liver disease was initially suspected in a subtype of progressive familial intrahepatic cholestasis called PFIC3. Several MDR3 mutations have been identified in children with PFIC3 and are associated with a low level of phospholipids in bile, leading to a high biliary cholesterol saturation index. Mutations leading to a truncated protein are associated with an absence of canalicular MDR3 protein. The phenotypic spectrum of PFIC3 ranges from neonatal cholestasis to cirrhosis in young adults. There is now strong evidence that in addition to PFIC3, an MDR3 defect can be involved in intrahepatic cholestasis of pregnancy and in cholesterol gallstone disease. Therefore, at least three human liver diseases are due to a single gene deficiency. Patients with PFIC3 due to MDR3 deficiency may benefit from ursodeoxycholic acid therapy and could be good candidates for cell therapy in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“UDCA has been reported to improve biochemical tests in almost 50% of patients with PFIC3 [172], but generally does not affect PFIC1 and PFIC2.”
BackgroundKhan, S. A., Thomas, H. C., Davidson, B. R., & Taylor-Robinson, S. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67530-7 · Cited by 1,042
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
“linked to ICP (Jacquemin, 2001; Wasmuth et al., 2007).”
BackgroundProgressive familial intrahepatic cholestasis
Davit-Spraul, A., Gonzales, E., Baussan, C., & Jacquemin, E. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-1 · Cited by 482
Self-citationBile Acid Metabolism and Signaling
Chiang, J. Y. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00517.x · Cited by 279
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis
Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Marschall, H.-U., Zatloukal, K., Denk, H., & Trauner, M. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00096-5 · Cited by 275
Popov, Y., Patsenker, E., Fickert, P., Trauner, M., & Schuppan, D. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.025 · Cited by 268
Progressive Familial Intrahepatic Cholestasis
Srivastava, A. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2013.10.005 · Cited by 268
New molecular insights into the mechanisms of cholestasis
Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 260
Kondrackiene, J., Beuers, U., & Kupcinskas, L. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.019 · Cited by 247
The Origin and Fate of Liver Myofibroblasts
Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.008 · Cited by 63
“66,68,69 At the onset of cholestatic injury (5 days post-BDL), aPFs comprised w 70% of liver myo fi broblasts and strongly upregulated collagen type I (to the level similar to that observed in CCl 4 -activated HSCs).”
Background
Metadata
- Authors
- Jacquemin, E.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 21
- Issue
- 04
- Pages
- 551-562
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2037740351
- Cited by
- 171
- References
- 0
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.